Debt-Free Balance SheetA debt-free balance sheet reduces financial risk and refinancing pressure, providing flexibility for future strategic investments.

Gene-Therapy FocusThe focus on gene-therapy for neurological diseases positions the company in a high-potential market with growing demand for innovative treatments.

Cash Flow TrackingClose tracking of cash flow to net income indicates efficient cash management, which is crucial for sustaining operations during loss-making periods.

Bears Say

Revenue DeclineA sharp decline in revenue indicates challenges in maintaining sales momentum, which could hinder long-term growth and market competitiveness.

Sustained Cash BurnSustained cash burn reflects ongoing financial strain, potentially limiting the company's ability to invest in R&D and future growth initiatives.

Equity DeclineA decline in equity suggests value erosion, which could impact investor confidence and the company's ability to raise capital in the future.

LARK FAQ

What was CombiGene AB’s price range in the past 12 months?

CombiGene AB lowest stock price was kr2.10 and its highest was kr2.87 in the past 12 months.

What is CombiGene AB’s market cap?

CombiGene AB’s market cap is kr44.75M.

When is CombiGene AB’s upcoming earnings report date?

CombiGene AB’s upcoming earnings report date is Aug 21, 2026 which is in 186 days.

How were CombiGene AB’s earnings last quarter?

CombiGene AB released its earnings results on Feb 13, 2026. The company reported kr0.01 earnings per share for the quarter, beating the consensus estimate of N/A by kr0.01.

Is CombiGene AB overvalued?

According to Wall Street analysts CombiGene AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CombiGene AB pay dividends?

CombiGene AB pays a Notavailable dividend of kr1.93 which represents an annual dividend yield of 8.47%. See more information on CombiGene AB dividends here

What is CombiGene AB’s EPS estimate?

CombiGene AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CombiGene AB have?

CombiGene AB has 19,801,197 shares outstanding.

What happened to CombiGene AB’s price movement after its last earnings report?

CombiGene AB reported an EPS of kr0.01 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.83%.

Which hedge fund is a major shareholder of CombiGene AB?

Currently, no hedge funds are holding shares in SE:LARK

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

CombiGene AB

Lärkberget AB (publ) operates as an investment company. It is involved in Direct investments in low-risk instruments; Financial investments; Direct investments in unlisted profitable companies; and Reverse acquisition platform. The company was formerly known as CombiGene AB (publ) and changed its name to Lärkberget AB (publ) in June 2025. Lärkberget AB (publ) was incorporated in 1990 and is based in Östermalm, Sweden.